STOCKS TELEGRAPH

Author: ST Staff

  • NRx Pharmaceuticals, Inc. (NRXP) Stock Surges ZYESAMI Role in Pandemic Response

    NRx Pharmaceuticals, Inc. (NRXP) Stock Surges ZYESAMI Role in Pandemic Response

    NRx Pharmaceuticals, Inc. (NRXP) stock prices skyrocketed by 42.84% shortly after market trading commenced on July 19th 2021, bringing the price per share up to USD$12.17 early on in the trading day.

    ZYESAMI’s Role in Covid-19

    July 21st, 2021 saw the company announce data about ZYESAMI (aviptadil) at the Disease Control and Prevention Summit., in regard to the role of the treatment in preventing Cytokine Storm in Covid-19 patients. The presentation will showcase the statistically significant effect of ZYESAMI in mitigating the sharp rise in cytokines, which are closely linked to mortality in Covid-19 patients. This was consolidated by the completion of a recent Phase 2b/3 trial of ZYESAMI, wherein the change in cytokine level was a prespecified endpoint.

    Details of the Study

    Patients treated in the study showed a minimal increase in IL-6, as compared to patients treated with a placebo reported a statistically significant elevation in interleukin 6 cytokine levels. The patient set was diverse, with varying levels of the severity of Covid-19 infection and distribution among both tertiary care and community hospitals.

    Accelerated Development

    The findings have been submitted to the U.S. Food and Drug Administration as supplements to the Emergency Use Authorization application that has been submitted as is currently pending. The company is also submitting a biomarker letter of intent to the FDA as a part of its biomarker program, as pre the authorization of the 21st Century Cures Act.

    Scope of ZYESAMI

    With Covid-19 hospitalizations continuing to rise around the world, the placebo-controlled biomarker data signals the critical role that ZYESAMI has the potential to play in the prevention of the sudden elevation of cytokines that is linked to mortality. A biomarker-based regulatory path seems cleared on the basis of the link established between the clinical effect of ZYESAMI on survival and recovery in conjunction with measurable biologic chance in cytokine levels. The effects of a cytokine storm are lethal and are associated with mortality resulting from a variety of fatal conditions, including, but not limited to, Acute Respiratory Distress Syndrome, a common cause of death in sepsis, and amniotic fluid embolus.

    Future Outlook for NRXP

    Armed with a highly promising advancement in the fight against the continuing global coronavirus pandemic, NRXP is poised to capitalize on the prospective market space that has become accessible to it. With such spearheaded market penetration, current and potential investors are hopeful that management will be able to leverage their resources to facilitate effective distribution of the offering in a timely manner to ensure maximum profitability.

  • ECMOHO Limited (MOHO) stock is gloomy today: What’s Going on?

    ECMOHO Limited (MOHO) stock is gloomy today: What’s Going on?

    Shares of the ECMOHO Limited (MOHO) stock were falling in today’s intraday trading on July 19, 2021, without any specific reason. The MOHO stock declined 7.38% to drop at $1.38 a share as of this writing. ECMOHO Limited is an investment holding company that provides integrated solutions to the health(non-medical) and wellness market. Let’s deep dive to explore more of it.

    What’s Happening?

    There is no MOHO stock-specific news in today’s date to justify the bearish sentiment. No analysts’ downgrades or shrank targeted per share price of the MOHO stock have been in the news to support today’s decline. It means MOHO stock is going down without any particular reason which is the general convention for most of the stocks as rises and falls are the norms of the stock market. So, what do you need to know now about this position? Let’s discuss some recent events of MOHO stock.

    Strategic Cooperation Agreement:

    On July 16, 2021, ECMOHO stock signed a strategic cooperation agreement with Chong Kundang Group, a pharmaceutical company in South Korea. The agreement was intended to provide the marketing as well as multichannel sales for retail solutions for Chong Kundang’s health products in China. Furthermore, the agreement would help CKD in providing high-quality diversified health and wellness products to  Chinese consumers.

    ECMOHO 618 Analysis:

    ECMOHO stock held sales event ECMOHO 618 on June 18, 2021, that was primarily focused on increasing trends and the concept of “comprehensive health” in products related to consumers’ health.MOHO stock collaborated with top domestic and foreign brands during the sales event in order to introduce high-quality health care products. Store traffic and sales had been increased via implementing multiple efficient strategies by the MOHO stock. The consumers and sales data had been gathered in order to reach a more targeted audience for high sales conversions of demanded products. Many reputed domestic and foreign brands had been empowered through ECMOHO 618 sales event in which Puritan’s Pride, Harbin Pharmaceutical, Wyeth, and Nestlé were also included.

    Financial View of the MOHO stock:

    According to first-quarter 2021 financial results, product sales revenue decreased to US$26.4 million from US$60.7 million in the same tenure of 2020. On the other hand, services revenue surged to US$679,648 in the recently reported quarter from US$440,147 in the first quarter of 2020. The gross margin of product sales was 18% and 61% for the services as well.

    Conclusion:

    MOHO stock is facing a bearish sentiment today despite the absence of any reason. Consumers are now more concerted to their health issues and health-related consumption after the rise of the Covid-19 pandemic. As MOHO stock is fully dedicated to fulfilling the needs of its consumers but first quarter of 2021 financial results were down as compared to the same quarter of the previous year. Hence investors are encouraged to do deep research before making any decision.

  • Ethereum coin price prediction: Price target at $2,250

    Ethereum coin price prediction: Price target at $2,250

    Ethereum coin continues its downtrend although at a decreased rigor. At the time of writing, Ethereum coin stands at a price level of $1,818. The price has fallen by 5% in the past twenty-four hours while the trading volume has decreased by 10%. ETH coin continues to vie for bullish momentum but with strong bear dominance, a bullish divergence cannot be sustained by the cryptocurrency.

    Ethereum coin technical analysis

    The market sentiment for cryptocurrency continues to be bearish. Out of the total twenty-six technical indicators, sixteen are giving out an indication of sell with the remaining ten indicators standing at a neutral position and zero signals at bullish indication.

    Ethereum Coin Technical Analysis
    Ethereum Coin Technical Analysis

    Although the market outlook for Ethereum coin is bearish in the shorter timeframes, would the bearish divergence continue or can the bulls be expected to dominate the market? Per a trader’s analysis, ETH has been identified to be operating in a falling wedge formation. The falling wedge is a bullish pattern. Per the analysis, Ethereum coin has also formed a coherent wave count inside the falling wedge. A pullback from the lower boundary of the formation can be expected in the upcoming days. If the pullback is successful and the onset of bullish momentum begins, a break out from the formation will become likely. In that case, the potential price target set at $2,250 will be activated.

    What is going on in Ethereum coin’s space? 

    Ethereum – the second-largest cryptocurrency – is an integral part of the crypto space because of its offering of decentralized finance through smart contracts. The aim of the network is to become the global platform for decentralized apps. The decentralized finance lending network Aave has announced to “build Twitter on Ethereum”. The co-founder of Aave, StaniKulechov, has tweeted the platform will give greater control to the audience. The news is one example of what Ethereum is capable of while the crypto space and its uses are still being explored.

  • Creatd, Inc. (CRTD) Stock Soars as Latest Target of Meme Stock Phenomenon

    Creatd, Inc. (CRTD) Stock Soars as Latest Target of Meme Stock Phenomenon

    Creatd, Inc. (CRTD) stock prices surged by 14.73% shortly after market trading commenced on July 19th, 2021, bringing the price per share up to USD$3.66 early on in the trading day.

    Vocal+ Success

    June 30th, 2021 saw the company report having achieved a significant milestone in having surpassed 30,000 subscribed users of Vocal+, the CRTD’s premium subscription offering of its flagship product, Vocal. The Vocal+ platform was launched earlier in 2020 after three years of its predecessor having driven the main business. Cumulatively, Vocal reports more than 1 million freemium and Vocal+ premium members that comprise its innovative creator community.

    Continued Development

    In light of these promising developments, the company forecasts reporting USD$1 million in net revenues for the second quarter of 2021, which will see a threefold increase from the numbers reported for the same quarter of the prior year. The upcoming quarter is set to see the company allocate resources towards the delivery of additional features that will enhance CRTD’s ability to expand and consolidate its creators and their audiences while driving down marketing costs. The company will, then, rely less on traditional paid media avenues while leveraging the organic traction of their strong network of 39 creator communities.

    Financial Guidance

    In tandem with the company’s newly released Vocal Ambassador Program, CRTD has found itself to have gained access to a source of organic growth for the platform. With the company expected to continue growing, it anticipates its creator-first strategy to generate anywhere from USD$1.6 million to USD$1.8 million in revenues for the third quarter of 2021. With a USD$1.5 million reductions in marketing costs, CRTD forecasts operating expenses in the amount of USD$3.3 million for Q3 2021

    Meme Stock Phenomenon

    Despite these promising developments, the lack of recent news or changes in fundamentals points to CRTD having become the latest target of the meme stock phenomenon. With retail investors coordinating to execute short squeezes on underdog companies with high floats, the phenomenon has been upending institutional investors over the past several quarters. Rife with volatility and risk, these gains are not something CRTD can expect to sustain for very long.

    Future Outlook for CRTD

    Despite the fleeting nature of the meme stock phenomenon’s touch, CRTD is poised to capitalize on the momentum generated by its increased scope of exposure. In a bid to use that limelight to prove to investors that they can justify such surges in stock price on merit, CRTD is keen to facilitate the resources at its disposal to drive in more organic growth over the long term.

  • Why Cytokinetics, Incorporated (CYTK) stock is soaring today?

    Why Cytokinetics, Incorporated (CYTK) stock is soaring today?

    Cytokinetics, Incorporated (CYTK) stock today announced positive topline results of Redwood-HCM after which the CYTK stock price soared by 52.00% to reach $29.23 a share at the time of this writing. Redwood HCM is the clinical trial of CK-274 in patients suffering from obstructive HCM(oHCM). Before this announcement, the stock was declining and dropped by 0.47% at the previous closing. Let’s understand more about recent events.

    Redwood-HMC results review:

    According to the results of Redwood-HCM’s cohort 1 and 2, 10 weeks of treatment with CK-274 has resulted in significant statistical reductions from baseline as compared to placebo. 78.6% of patients treated with CK-274 in cohort 1 and 92.9% in cohort 2. Majority out of these patients have achieved the desired results of the treatment. The target goal was resting gradient below 30 mmHg and post-Valsalva gradient  (LVOT-G) below  50 mmHg at Week 10 compared to placebo. The reductions in LVOT-G were started in the first two weeks of the treatment and became maximum till the end of the sixth week of the treatment. The reductions were sustained for the rest of the remaining weeks of the treatment. It was observed that the reductions in LVOT-G were proportional to the doses of CK-274.

    There were no serious adverse effects observed during the treatment with CK-274 and no interruptions occurred. One patient in the dose range-finding trial experienced a transient decrease in left ventricular ejection fraction (LVEF). This problem was related to the dose adjustment rather than dose interruption.

    Previous Activity by CYTK stock:

    CYTK stock at the beginning of this month on July 01, 2021, did announce that it had granted stock options to its twelve new employees on June 30, 2021. According to the stock option, the 12 new employees were eligible to purchase an aggregate of 90,000 shares of common stock. The Cytokinetics’ board of directors Compensation and Talent Committee had approved the grant before. The exercise price was  $19.79 per share of the CYTK stock which was the closing price on June 30, 2021.

    Wrap Up:

    Investors are responding positively to the positive results of Redwood-HCM. The trading volume of the CYTK stock today is far above the average so far. The planned phase three registrational clinical trial of CK-274 is expected to begin before the end of the current year.

  • Conformis, Inc. (CFMS) Stock on the Rise as it Prepares to Present at Canaccord Genuity 40th Annual Growth Conference

    Conformis, Inc. (CFMS) Stock on the Rise as it Prepares to Present at Canaccord Genuity 40th Annual Growth Conference

    Conformis, Inc. (CFMS) stock prices were up 7.62% as of market trading closing on July 16th, 2021, bringing the price per share up to USD$1.13 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 6.19%, bringing it up to USD$1.23.

    Settlement Agreement

    July 7th, 2021 saw the company announce having entered into a settlement agreement with Stryker Corp., thus putting to rest ongoing patent litigation in regard to Wright Medican Technology and Tornier, which were acquired by Stryker in November of 2020. The resolution of the patent litigation over the Wright Medical dispute signals the strength and value of the company’s intellectual property, as well as their unwavering commitment.

    Details of the Lawsuit

    April 24th, 2020 had seen CFMS file a lawsuit against Wright Medical in the United States District Court for in Delaware. The lawsuit alleged that the defendant’s various lines of patient-specific shoulder instruments infringed existing patents, as did implant components used in conjunction with the instruments. As per the terms of the settlement agreement, Stryker is set to make a one-time payment to CFMS, which will grant it a non-exclusive license for some of the company’s patents.

    Distribution Agreement

    June 23rd, 2021 had seen the company announce the execution of an agreement with XR Medical Group, which would see the company enter the Asia-Pacific market through an exclusive distribution relationship. As per the distribution agreement, XR Medical will be granted exclusive rights for the sale, marketing, and distribution of CFMS’ patient-specific iTotal CR and PS total knee replacement systems. Also included in the agreement are the iTotal CR and PS patella devices, as well as the iUni and iDuo partial knee replacement systems. The agreement also allows for the proactive additional of CFMS’s expanding product portfolio into the terms of the agreement.

    Scope of Market

    With the global market for knee joint reconstruction being pegged in excess of USD$9 billion, the Asia-Pacific region makes up an estimated USD$1.7 billion of the burgeoning marketspace. The company is keen to see the fruition of Fortune Business Insights’ forecasts of continued increases in the rate of growth, stemming largely from an increased prevalence of knee disorders, surges in medical tourism, higher disposal incomes, as well as improved healthcare infrastructure.

    Future Outlook for CFMS

    Armed with the resolution to their litigation issues, the company is poised to allocate its resources towards penetrating the newly accessed Asia-Pacific market. CFMS is keen to push for the continued commercialization and increased proliferation of its myriad of treatment options. Investors are hopeful that management will be able to usher in significant and sustained increases in shareholder value over the long term.

  • Carnival Corp & PLC (CCL) Stock Continues Downward Spiral as Florida Refuses Proof of Vaccination Requirement

    Carnival Corp & PLC (CCL) Stock Continues Downward Spiral as Florida Refuses Proof of Vaccination Requirement

    Carnival Corp & PLC (CCL) stock prices were down by 4.69% as of the market closing on July 16th 2021, bringing the price per share down to USD$20.92 at the end of the trading day. Subsequent premarket fluctuations have seen the stock fall by another 4.45%, bringing it down to USD$19.99.

    Seabourn Ovation

    July 14th 2021 saw the company announce the opening of the sale of its serious of new itineraries for Seabourn Ovation, which is expected to commence operation out of Miami between November 2021 and April 2022. This will coincide with the ship’s first-ever stop at a United States port on November 18th 2021. This will make the first Caribbean cruise for the Seabourn Ovation, which will start with three 11-day voyages from Miami, where it will also conclude. Trips will depart on November and December of 2021.

    Forecasted Itineraries

    The ship will go on to explore the Panama Canal and areas in Central America between December 2021 and March 2022. January 30th 2022 will see Seabourn Ovation set sail to Centra America with four roundtrip voyages departing from Miami. Customers who book one of the several new itineraries by August 31st 2021 will be granted Shipboard Credit of up to USD$1000, or up to USD$2000 in Shipboard Credit for a Penthouse or Premium Suite.

    Post-Pandemic Operations

    With the world’s continued efforts towards universal immunizations against the coronavirus pandemic, the company is keen to see the persistent easing of mobility restrictions around the globe. With more than 50% of the company’s capacity scheduled to resume sailing by Fall of 2021, CCL is hopeful to make a recovery from the devastating effects of the onset of the pandemic. Promisingly, bookings for 2022 are higher than just before the pandemic, with pent-up demand having burgeoned.

    Continued Effects of Pandemic

    The momentum generated, however, has recently been slowing down. This is largely due to an official announcement by the Government of Florida that denies cruise ship operators from enforcing passengers to show proof of vaccinations. This could result in the implementing of mandatory Covid-19 travel insurance, which would adversely affect demand. The company is keen to see the continued easing of restrictions on travel and mobility.

    Future Outlook for CCL

    With the world hurtling towards an end to the global coronavirus pandemic, CCL is poised to capitalize on the return of the global economy to pre-pandemic levels. Investors are hopeful that the company will be able to ramp up its operations even in light of partial removals of restrictions, with the eventual resumption of normal operations bringing in unprecedented growth as a result of long-term, pent-up demand.

  • Windtree Therapeutics, Inc. (WINT) Stock Exhibits Minor Volatility Despite Promising Istaroxime Developments

    Windtree Therapeutics, Inc. (WINT) Stock Exhibits Minor Volatility Despite Promising Istaroxime Developments

    Windtree Therapeutics, Inc. (WINT) stock prices were down by 6.56% as of the market closing on July 16th2021, bringing the price per share down to USD$1.71 at the end of the trading day. Premarket fluctuations saw the stock rise by 6.43%, bringing it up to USD$1.82.

    Istaroxime Study

    May 2021 saw the company reiterate the expansion of the counties and sites participating in its Phase 2 global clinical study. The study is for istaroxime, which is being evaluated as a viable treatment option for Early Cardiogenic Shock in patients having suffered from severe acute heart failure. A severe form of heart failure, cardiogenic shock is marked by critically low blood pressure. The development of the treatment is founded in observations from the acute heart failure program and will serve to assess istaroxime’s ability to improve blood pressure. The study is expected to be completed by the second half of 2021.

    Istaroxime Patent Protection

    The company has also been seeking additional expedited patent protection for istaroxime, their lead asset. To facilitate this, WINT filed a Track One prioritized patent application with the U.S Patent and Trademark Office, with the associated patent being derived from an application previously filed under the Patent Cooperation Treaty. As per the Track One program, the new patent for istaroxime is forecasted to receive a review and final disposition according to an accelerated timeline. The priority status being granted, the company expects finalizations within a year, as compared to the typical three-year examination for non-prioritized examinations.

    Solid Liquidity Position

    The first quarter of 2021 saw WINT complete an equity financing program, which saw the company generate almost USD$30 million in gross proceeds, before the deduction of expenses related to the offering. Net proceeds from the offering came out to roughly USD$27.4 million, contributing to the company’s solid liquidity position as of March 31st, 2021, when WINT announced having cash and cash equivalents in the amount of USD$38.5 million.

    Net Loss Reports

    WINT reported a net loss of USD$9 million on 17.7 million weighted-average common shares outstanding as of the end of the first quarter of 2021, representing a net loss of USD$0.57 per basic share. The is comparable to the UD$6.5 million net loss reported for the prior-year period, which had 13.7 million weighted average common shares outstanding, representing a net loss of USD$0.48 per basic share.

    Future Outlook for WINT

    Armed with a comfortable liquidity position and strategic partnerships that aim to develop treatments through to commercialization and proliferation, WINT is poised to capitalize on the opportunities afforded to it. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • How Did The Kosmos (KOS) Stock Rise 5% In Extended Trades?

    How Did The Kosmos (KOS) Stock Rise 5% In Extended Trades?

    Kosmos Energy Ltd. (KOS) gained 4.33% to trade at $2.41 in after-hours trading on Friday. Kosmos closed at $2.31 after falling -7.23% during the regular session. There were 9.56 million shares traded of KOS stock, which is a larger amount than the average volume for the past three months of 7.02 million shares. During the regular session, KOS fluctuated from $2.30 to $2.60.

    With an earnings ratio of -0.79, KOS had negative earnings per share. On a year-to-date basis, KOS stock has lost -1.70% but the loss rises to -24.51% in the past five sessions. As of Friday, KOS has an SMA-50 of $3.20, higher than its 200-day moving average of $2.54. Also, the RSI of KOS trades at 28.65.

    As KOS stock recovered in the extended trades when no new information was available, so there may be some reason to believe that recent developments will reveal new information about the KOS.

    What has been happening at KOS lately?

    Kosmos is an independent deepwater oil and gas exploration and production company focusing on the Atlantic Margin. One of KOS’s key assets is a world-class gas development offshore Mauritania and Senegal, as well as production offshore Ghana, Equatorial Guinea, and the Gulf of Mexico. In keeping with its ethical, transparent, and professional ethos, KOS does things the right way. The KOS Business Principles identify the company’s commitment to transparency, ethics, human rights, environmental protection, and safety.

    A recent operational report by Kosmos Energy elaborated upon the company’s production, development, and exploration activities.

    • It is ahead of KOS’ financial results for the second quarter, which will be released on August 9, 2021.
    • With infill drilling planned in all three hubs, KOS has an active second half of the year, which is supportive of near-term production growth.
    • As well, KOS plans to relaunch exploration and appraisal drilling for the Winterfell appraisal well and Zora ILX well this quarter.
    • KOS is in a strong position to create shareholder value throughout the rest of 2021 as oil prices rise and its financial position strengthens.
    • In line with guidance, KOS’ sales volumes in the second quarter averaged 66,000 barrels of oil equivalent per day (boepd), with 4.5 cargos lifted.
    • During the second quarter, net production at KOS averaged approximately 52,000 boepd, a modest decline primarily due to lower production in Equatorial Guinea.
    • KOS plans to produce 53,000 to 57,000 boepd for the full year, with an additional 60,000 boepd expected to be produced from new wells by year-end.

    How does KOS anticipate the second quarter?

    As a result of higher sales volumes, strong operational performance in Ghana, and rising realized oil prices, Kosmos (KOS) generated positive cash flow in the second quarter that helped to reduce its net debt by around $100 million. With a new drilling rig has been sent to Equatorial Guinea for development drilling, and two new oil wells were drilled in Ghana and the U.S. Gulf of Mexico, KOS has been seeing increase in production across its hubs during the quarter.

  • Has Histogen (HSTO) Stock Risen in Extended Session For A Reason?

    Has Histogen (HSTO) Stock Risen in Extended Session For A Reason?

    The shares of Histogen Inc. (HSTO) rose 5.87% to $0.8799 in Friday’s after-hours trading. At the end of the regular trading session, Histogen stock closed at $0.83, down -1.01%. The volume of shares traded on HSTO stock was 0.44 million, which is below the average daily trading volume of 1.89 million shares for the past 50 days.

    In the last five days, HSTO stock has declined -14.27%, but over the past month, they have lost -17.71%. The HSTO stock price has fallen by -19.31% over the past three months and is down by -72.11 percent year-to-date. Due to the HSTO stock’s rise in the absence of current news, developments have been observed that lend clarity to HSTO’s current situation.

    Have things been going well at HSTO lately?

    In addition to developing potential first-in-class restorative therapeutics, Histogen engages the body’s natural mechanisms for repairing and maintaining healthy biological function. Hypoxia-induced multipotent cells produce cell conditioned media and extracellular matrix materials for HSTO’s innovative technology platform. With its proprietary, reproducible manufacturing process, HSTO offers tailored solutions across a wide range of therapeutic indications, including joint cartilage regeneration, spinal disk repair, and dermal rejuvenation.

    Histogen recently announced that it will begin testing its HST 003 in Phase 1/2 clinical trials.

    • Human extracellular matrix (hECM:HST 0003) was implanted within microfracture interstices or cartilage defects in the knee in order to restore hyaline cartilage in conjunction with a microfracture procedure in the HSTO trial.
    • Walter Reed Medical Center in Bethesda, MD, The Steadman Clinic in Vail, CO, and OasisMD in San Diego, CA, are participating in HSTO’s trial.
    • By using a novel scaffold that stimulates the body’s own stem cells, HSTO’s hECM aims to regenerate hyaline cartilage for the treatment of articular cartilage defects.
    • A number of preclinical studies have demonstrated that HST 003 regenerates mature cartilage and well-vascularized bone, which suggests great therapeutic potential in sports medicine, spinal disc repair, orthopedic, and dental fields.
    • HSTO’s double-blind placebo-controlled trial aims to evaluate whether hECM can regenerate hyaline cartilage in combination with microfracture in microfracture interstices and cartilage defects in the knee.
    • Safety assessments, MRI scans to check for cartilage regeneration, and Knee Injury and Osteoarthritis Outcome Score (KOOS) and International Knee Documentation Committee (IKDC) scores will serve as primary and secondary endpoints, respectively.

    The trial will help HSTO grow in what ways?

    A significant milestone has been achieved for Histogen (HSTO) with the initiation of the HST 003 clinical trial. With the trial, HSTO will continue to work on developing top-of-the-line orthopedic therapeutics based on its regenerative medicine platform technology.